Arcus Biosciences, Inc.: shareholders and insiders

RCUSNYSEHealthcare · Pharmaceutical Preparations

Price

$15.76

November 18, 2026Market cap $2.3B

What Ploutos Investor adds for Arcus Biosciences

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 9 fiscal years, from 2017
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.

Insiders and their shares

Purchases and sales by officers and directors from Nov 19, 2025 to Aug 24, 2026, from their own Form 4 filings.

12 Form 4s

Bought on the market

–

nobody

Sold on the market

$9.2M

7 people

From Nov 19, 2025 to Nov 19, 2026, the days the chart shows. Change its range and the figures follow.

How the sales were made, as a share of their value

  • Under a set plan100%
  • The rest0%

By year

Insiders' open-market purchases (up) and sales (down), by value, since Nov 19, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.

2026·no buys·sold $3.9M by 3 people

  • 2025: no buys, sold $5.3M by 7 people
  • 2026: no buys, sold $3.9M by 3 people
  • Aug 21, 2026Alexander AzoyChief Accounting Officer
    Kind10b5-1
  • Aug 21, 2026Alexander AzoyChief Accounting Officer
    Kind10b5-1
  • Jul 10, 2026Juan C. JaenPresident
    Kind10b5-1
  • Jul 10, 2026Juan C. JaenPresident
    Kind10b5-1
  • Jul 9, 2026Juan C. JaenPresident
    Kind10b5-1
  • Jun 24, 2026Juan C. JaenPresident
    Kind10b5-1
  • Jun 23, 2026Juan C. JaenPresident
    Kind10b5-1
  • Jun 23, 2026Juan C. JaenPresident
    Kind10b5-1
  • Jun 22, 2026Juan C. JaenPresident
    Kind10b5-1
  • Jun 11, 2026Nicole LambertDirector
    Kind
  • Jun 11, 2026Patrick MachadoDirector
    Kind
  • Jun 11, 2026Yasunori KanekoDirector
    Kind
  • Jun 11, 2026Carolyn C. TangGeneral Counsel
    Kind
  • Jun 11, 2026David L. LaceyDirector
    Kind
  • Jun 11, 2026Kathryn E FalbergDirector
    Kind
  • Jun 11, 2026Antoni RibasDirector
    Kind
  • Jun 11, 2026Andrew J PerlmanDirector
    Kind
  • Jun 1, 2026Alexander AzoyChief Accounting Officer
    Kind10b5-1
  • May 11, 2026Robert C. Goeltz IIChief Financial Officer
    Kind10b5-1
  • Jan 5, 2026Juan C. JaenPresident
    Kind10b5-1
  • Jan 5, 2026Juan C. JaenPresident
    Kind10b5-1
  • Jan 5, 2026Juan C. JaenPresident
    Kind10b5-1

From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 1, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.

Insiders and their shares

Every buy and sale by RCUS's officers and directors from 2018 up to November 18, 2025, 8 more calendar years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 3 years.

Major holders (over 5%)

Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.

2 Holders over 5%1 On a 13DAug 7, 2026 Latest filing
  • Gilead Sciences, Inc.
    Share of class24.7%
  • BlackRock, Inc.
    Share of class10.4%

What the holders on a 13D state as their purpose

From Item 4 of the filing, in the holder's own words. It is the intention the holder states, not something that happened.

  • Gilead Sciences, Inc.24.7%From the filing of Aug 7, 2026

    On May 27, 2020, Gilead and the Issuer entered into an Option, License and Collaboration Agreement (the "Collaboration Agreement") pursuant to with Gilead obtained an exclusive option to acquire an exclusive license to all of the Issuer's current and future clinical programs during the 10-year collaboration term and, for those programs that enter clinical development prior to the end of the collaboration term, for up to an additional three years thereafter. In addition to the Collaboration Agreement, Gilead and the Issuer entered into a Common Stock Purchase Agreement (the "Purchase Agreement"), which was amended and restated on January 31, 2021 to account for the Second Purchase (the…

    From the filing of Aug 7, 2026
Fell to 5% or less (2)

Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.

  • The Vanguard Group0.00%Mar 26, 202613G/A
  • Point72 Asset Management, L.P.4.10%Nov 14, 202513G/A

From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.

Well-known managers

Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.

Sep 30, 2026 quarter end
  • Citadel Advisors (Griffin)
    In the quarter-5.6%
  • Point72 (Cohen)
    In the quarter
  • Millennium Mgmt (Englander)
    In the quarter-26%
  • D.E. Shaw
    In the quarter-0.6%
  • Renaissance Technologies
    In the quarter
  • AQR Capital
    In the quarter+5.9%

From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).

Short interest

How many of the company's shares have been sold borrowed and not yet bought back, twice a month.

On Oct 15, 2026, 8.58% of its shares outstanding were held short, -5.7% since the report before.

Shares held short
12.36M
8.58%
Since the report before13.11M on Sep 30, 2026
-5.7%
9.7
1.28M
More days to cover thanof 4,578 US-listed companies with enough volume
90%
Report date
Oct 15, 2026
  • Oct 31, 2023: Shares held short 6.92M
  • Nov 15, 2023: Shares held short 6.02M
  • Nov 30, 2023: Shares held short 6.58M
  • Dec 15, 2023: Shares held short 6.77M
  • Dec 29, 2023: Shares held short 7.27M
  • Jan 12, 2024: Shares held short 7.15M
  • Jan 31, 2024: Shares held short 7.00M
  • Feb 15, 2024: Shares held short 7.52M
  • Feb 29, 2024: Shares held short 7.68M
  • Mar 15, 2024: Shares held short 7.98M
  • Mar 28, 2024: Shares held short 8.25M
  • Apr 15, 2024: Shares held short 6.84M
  • Apr 30, 2024: Shares held short 7.75M
  • May 15, 2024: Shares held short 7.54M
  • May 31, 2024: Shares held short 7.43M
  • Jun 14, 2024: Shares held short 7.91M
  • Jun 28, 2024: Shares held short 6.16M
  • Jul 15, 2024: Shares held short 6.64M
  • Jul 31, 2024: Shares held short 6.62M
  • Aug 15, 2024: Shares held short 6.97M
  • Aug 30, 2024: Shares held short 6.74M
  • Sep 13, 2024: Shares held short 6.90M
  • Sep 30, 2024: Shares held short 6.61M
  • Oct 15, 2024: Shares held short 6.34M
  • Oct 31, 2024: Shares held short 6.65M
  • Nov 15, 2024: Shares held short 7.57M
  • Nov 29, 2024: Shares held short 8.03M
  • Dec 13, 2024: Shares held short 7.39M
  • Dec 31, 2024: Shares held short 7.75M
  • Jan 15, 2025: Shares held short 8.25M
  • Jan 31, 2025: Shares held short 6.38M
  • Feb 14, 2025: Shares held short 6.47M
  • Feb 28, 2025: Shares held short 6.88M
  • Mar 14, 2025: Shares held short 7.42M
  • Mar 31, 2025: Shares held short 8.45M
  • Apr 15, 2025: Shares held short 9.65M
  • Apr 30, 2025: Shares held short 7.91M
  • May 15, 2025: Shares held short 9.90M
  • May 30, 2025: Shares held short 11.49M
  • Jun 13, 2025: Shares held short 10.47M
  • Jun 30, 2025: Shares held short 10.97M
  • Jul 15, 2025: Shares held short 10.05M
  • Jul 31, 2025: Shares held short 8.97M
  • Aug 15, 2025: Shares held short 9.10M
  • Aug 29, 2025: Shares held short 9.83M
  • Sep 15, 2025: Shares held short 10.90M
  • Sep 30, 2025: Shares held short 9.89M
  • Oct 15, 2025: Shares held short 8.65M
  • Oct 31, 2025: Shares held short 8.34M
  • Nov 14, 2025: Shares held short 9.89M
  • Nov 28, 2025: Shares held short 9.09M
  • Dec 15, 2025: Shares held short 7.83M
  • Dec 31, 2025: Shares held short 9.59M
  • Jan 15, 2026: Shares held short 8.90M
  • Jan 30, 2026: Shares held short 8.20M
  • Feb 13, 2026: Shares held short 9.01M
  • Feb 27, 2026: Shares held short 9.27M
  • Mar 13, 2026: Shares held short 8.61M
  • Mar 31, 2026: Shares held short 9.88M
  • Apr 15, 2026: Shares held short 11.07M
  • Apr 30, 2026: Shares held short 10.88M
  • May 15, 2026: Shares held short 10.89M
  • May 29, 2026: Shares held short 11.71M
  • Jun 15, 2026: Shares held short 13.27M
  • Jun 30, 2026: Shares held short 12.64M
  • Jul 15, 2026: Shares held short 12.56M
  • Jul 31, 2026: Shares held short 13.12M
  • Aug 14, 2026: Shares held short 13.85M
  • Aug 31, 2026: Shares held short 13.08M
  • Sep 15, 2026: Shares held short 13.81M
  • Sep 30, 2026: Shares held short 13.11M
  • Oct 15, 2026: Shares held short 12.36M

As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.

Short sales in daily trading46.7% of the shares in the last 14 sessions' reported trades were short sales.

In the last 14 sessions, 46.7% of the shares in the reported trades were short sales, against 42.3% in the 14 before.

Last 14 sessionsOct 30, 2026 – Nov 18, 2026
46.7%
The 14 beforeOct 12, 2026 – Oct 29, 2026
42.3%
Change
+4.4 pts
Short sales a dayon average, of 489.1K shares
228.5K
More than atof 3,656 US-listed companies, same days
37%
Median of alleight in ten from 34.4% to 63.7%
50.3%
  • Oct 12, 2026: Short sales 50.2%
  • Oct 13, 2026: Short sales 57.2%
  • Oct 14, 2026: Short sales 61.9%
  • Oct 15, 2026: Short sales 38.5%
  • Oct 16, 2026: Short sales 59.4%
  • Oct 19, 2026: Short sales 49.3%
  • Oct 20, 2026: Short sales 30.1%
  • Oct 21, 2026: Short sales 43.1%
  • Oct 22, 2026: Short sales 24.3%
  • Oct 23, 2026: Short sales 45.2%
  • Oct 26, 2026: Short sales 64.4%
  • Oct 27, 2026: Short sales 54.2%
  • Oct 28, 2026: Short sales 51.2%
  • Oct 29, 2026: Short sales 49.9%
  • Oct 30, 2026: Short sales 29%
  • Nov 2, 2026: Short sales 61.9%
  • Nov 3, 2026: Short sales 43.5%
  • Nov 4, 2026: Short sales 37.1%
  • Nov 5, 2026: Short sales 75.1%
  • Nov 6, 2026: Short sales 57.3%
  • Nov 9, 2026: Short sales 60.8%
  • Nov 10, 2026: Short sales 33.8%
  • Nov 11, 2026: Short sales 38.4%
  • Nov 12, 2026: Short sales 41%
  • Nov 13, 2026: Short sales 55.8%
  • Nov 16, 2026: Short sales 59.2%
  • Nov 17, 2026: Short sales 39.4%
  • Nov 18, 2026: Short sales 29.1%

This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.

What the insiders hold

The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.

36.75M Insiders' shares29.32% Of the company
  • Gilead Sciences, Inc.TenPercentOwner
    Directly31.42M
  • Terry J RosenChief Executive Officer
    Directly2.19M
  • Juan C. JaenPresident
    Directly346.0K
  • Yasunori KanekoDirector
    Directly958.0K
  • Jennifer JarrettChief Operating Officer
    Directly193.0K
  • Carolyn C. TangGeneral Counsel
    Directly184.6K
  • Kathryn E FalbergDirector
    Directly176.4K
  • Robert C. Goeltz IIChief Financial Officer
    Directly84.2K
  • David L. LaceyDirector
    Directly76.7K
  • Richard MarkusChief Medical Officer
    Directly65.6K
  • Antoni RibasDirector
    Directly52.9K
  • Andrew J PerlmanDirector
    Directly48.3K
  • Patrick MachadoDirector
    Directly44.3K
  • Nicole LambertDirector
    Directly43.0K
  • Alexander AzoyChief Accounting Officer
    Directly39.6K

A lower bound: it counts only the 15 officers and directors with a market trade since Nov 20, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.

The ETFs that hold it

Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.

25 ETFs holding it0.74% The largest weight (XBI)
  • XBIState Street(R) SPDR(R) S&P(R) Biotech ETF
    Weight in the fund0.74%
  • LABUDirexion Daily S&P Biotech Bull 3X Shares
    Weight in the fund0.50%
  • IBBiShares Biotechnology ETF
    Weight in the fund0.20%
  • IJTiShares S&P Small-Cap 600 Growth ETF
    Weight in the fund0.18%
  • FESMFidelity Enhanced Small Cap Core ETF
    Weight in the fund0.16%
  • SPSMState Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETF
    Weight in the fund0.15%
  • IJRiShares Core S&P Small-Cap ETF
    Weight in the fund0.14%
  • IWOiShares Russell 2000 Growth ETF
    Weight in the fund0.13%
  • IJSiShares S&P Small-Cap 600 Value ETF
    Weight in the fund0.11%
  • IWMiShares Russell 2000 ETF
    Weight in the fund0.09%

25 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.

Institutional investors by quarter

Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.

230 Managers, Q2 2026$3.8B Value of their positions
  • Q3 2025: Managers 190
  • Q4 2025: Managers 209
  • Q1 2026: Managers 212
  • Q2 2026: Managers 230

Institutional investors by quarter

The fund managers holding RCUS, quarter by quarter, from Q1 2018 to Q2 2025, 30 more quarters

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 12 quarters.

Q2 2026: 230 managers held 123M shares, worth $3.8B. During the quarter 46 opened a position, 28 closed one, 84 added and 62 trimmed.

The largest holders, Q2 2026

  • Gilead Sciences
    In the quarter
  • BlackRock
    In the quarter+7.8%
  • State Street
    In the quarter+11%
  • Wellington Management Group
    In the quarter-3.2%
  • Montanova Capital
    In the quarter-5.1%
  • Vanguard Portfolio Management
    In the quarter+4.8%
  • FMR
    In the quarter+248%
  • Vanguard Capital Management
    In the quarter+0.8%
  • Citadel Advisors (Griffin)
    In the quarter+136%
  • Woodline Partners
    In the quarter-20%

From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.

Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.

The full analysis

What do Arcus Biosciences's filings show?

Who buys and sells is one part of Arcus Biosciences's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about RCUS's shareholders

Didn't find what you were looking for?

Ask us
Have RCUS's insiders bought or sold?

From Jun 1, 2026 to Aug 24, 2026 Arcus Biosciences's insiders bought 0 and sold $3.1M of shares on the market. 100% of the sales were under set 10b5-1 plans.

Which well-known managers hold RCUS?

6 of the managers we track held the shares on Sep 30, 2026. The largest position was Citadel Advisors (Griffin)'s, worth $77M.

Is every insider transaction a purchase or a sale?

No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.